Our company

Our Leadership

The Onkos Leadership team is dedicated to helping surgeons identify solutions to better help their patients who are living with these conditions. We strive to understand the clinical challenges that are faced every day by our surgeon customers.This motivates us to deliver on the promise of Precision Orthopaedics in the OR.


Patrick Treacy

President, Co-Founder and CEO

Patrick founded Onkos Surgical in 2015 with a simple purpose, known at Onkos as “Our Why” – that individuals with cancer and other complex orthopaedic conditions deserve solutions designed specifically for them. Patrick began his career as a product development engineer with Howmedica, later Stryker Orthopedics.  He advanced through numerous roles in R&D, marketing and general management as head of the Stryker global knee franchise.  During this time, Patrick developed a passion for the advancement of musculoskeletal oncology and complex orthopedics, seeing the need for unique and personalized solutions for these surgeons and their patients. Prior to founding Onkos, Patrick served as the President of PDI Healthcare.  Patrick earned a BSME in Mechanical Engineering from Villanova University and holds numerous implant and instrument design patents in orthopedic surgery.

Sean Curry

Senior Vice President, Commercial Operations

Sean has been with Onkos since we opened our doors in 2015, serving as the SVP, Commercial Operations and responsible for all Marketing, Business Development, Patient Solutions, and Training functions. Sean brings over 25 years of diverse leadership experience in orthopaedics with companies including Biomet, Inc., and Greatbatch, where he has held responsibility for various sales, marketing, development, and general management roles. As Biomet’s VP, Worldwide General Manager of Spine, Sean successfully led and managed a $200M global franchise after serving as the GM of Biomet Trauma. Throughout his career, Sean has been involved with the development of numerous impactful innovations in complex spinal deformity and various pediatric applications. He holds a B.A. from Connecticut College and completed executive management programs at The University of Notre Dame.

Bradly Tyler

SVP Finance and Administration

Brad has been with Onkos since we opened our doors in 2015. In his capacity as SVP of Finance, HR, and Administration, Brad has overseen the growth and investment across the company and through various stages, and brings a mix of financial acumen, administrative prowess, and healthcare industry experience. Prior to joining Onkos, Brad worked for 14 years at LifeCell Corporation, where he helped the company grow from $20 million in revenue to over $450 million. At LifeCell, he served as Vice President of Finance, Vice President of Performance Management, Interim Vice President of LifeCell Europe, and Controller. Brad earned a B.S. in Accounting from Louisiana State University.

Brian Brinson

Senior Vice President, Sales

Brian is a graduate of United States Military Academy at West Point where he earned a BS in Systems Engineering and was a tight end for the football team. While serving in the United States Army in positions of increasing responsibility and command, he also earned a Master’s in engineering management from Missouri S&T.  Prior to joining Onkos, Brian was a Regional Director at Abbott Neuromodulation. Before Abbott, Brian spent 11 years at Johnson & Johnson Depuy Synthes. At Depuy Synthes, Brian managed sports, trauma, biologics, and CMF. Brian was also a distributor principal at CMJ Medical, an award-winning distributor for Depuy Synthes, Arthrosurface, MTF, and others.

Gordon Ballard

VP Operations and Human Resources

Gordon joined Onkos in 2016 as VP of Operations with responsibility for establishing our manufacturing supply chain and distribution network. Gordon joined Onkos from DJO Surgical where he oversaw all reimbursement operations. Prior to that, Gordon progressed through various leadership positions at Stryker within its sales, marketing, and operations organizations while also leading acquisition integration and business planning teams. Gordon earned a B.S. from the United States Naval Academy and has completed executive leadership programs at Harvard Business School.

Matt Vernak

VP Quality Assurance and Regulatory Affairs

Matt joined Onkos in 2018 and has served in numerous roles of increasing capacity across our Quality and Regulatory functions while scaling both departments. Matt has led the team through various expansions of our Quality System while assuming responsibility for our Regulatory Affairs function. In this capacity, he oversees both our Quality System and our product-labeling and submission efforts. Prior to Onkos, Matt held positions of increasing responsibility that included Quality Systems leadership at both Pentax and LifeCell corporations. He began his career in pharmaceutical manufacturing and quality engineering in positions at both Merck and Pfizer. Matt holds a B.S. in Mechanical Engineering from Rutgers University.

Gary Thomas

Vice President of Manufacturing

Gary joined Onkos in 2022 as VP, Manufacturing and is responsible for building and scaling our manufacturing capabilities and partnerships to continue positioning our company for the future. Gary is a seasoned operational executive with extensive experience in aerospace and medical devices. Gary joined Onkos from Tyber Medical where he served as COO, leading the company through an unprecedented growth rate where Tyber was recognized as one of the fastest-growing medical device companies in the country. Gary also worked at Biomet as a Vice President of Global Operations in a transformational role with several private equity companies for approximately 7 years. In addition, he worked at MTF (Biologics) as Vice President of Operations for approximately 9 years managing operations, logistics and new product development on behalf of J&J Spine. His career started in aerospace, and transitioned into the medical device field with Pfizer, Howmedica, where he worked for 10 years handling roles of increasing responsibility in supply chain.

Antony Koblish

Founder, Chairman of the Board

Antony Koblish is currently CEO and President of TELA Bio, a surgical reconstruction company he co-founded in 2012. Prior to his position at TELA, he served as the Chief Executive Officer and President at Orthovita, a manufacturer of biologics for spinal surgery. Before his 11-year tenure at Orthovita, where he was promoted to Chief Executive from Director of Worldwide Marketing, Antony served as Director of Marketing and Product Development in the Reconstructive Specialty Group at Howmedica. He currently serves as a Director of CeraPedics, Orthobond, and The Pennsylvania Biotechnology Association. He has a B.S. in Mechanical Engineering from Worcester Polytechnic Institute and an M.S. in Engineering, Mechanical Engineering and Applied Mechanics from The University of Pennsylvania.

Adele Oliva

Partner and Co-Founder, 1315 Capital

Adele Oliva has been a healthcare investor for more than 20 years and focuses on commercial stage medical technology, healthcare services, and specialty therapeutic investments. Adele co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing and the firm has since raised two funds and has more than $500 million under management. She was recruited by Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.

Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.

Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Genoptix (acquired by NeoGenomics), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan). She currently serves on the boards of 3B Scientific, Colorescience, Greenbrook TMS, Innovative Health, miraDry, and Onkos Surgical.

Stephen Bloch, M.D.

General Partner, Canaan Partners

Stephen (“Steve”) is an entrepreneur and a general partner at Canaan partners.He currently serves on the boards of companies in biopharma (Liquidia [LQDA- NASDAQ Board Chairman], digital health [Truveris, Ambra Health, Corvium and Genome Medical], and medical devices [Onkos Surgical®]). Past board roles include Amicus Therapeutics (FOLD-NASDAQ), Marinus Pharmaceutical (MRNS-NASDAQ) and advanced BioHealing (M& with Shire). Steve is a member of Dartmouth Medical School’s Board of Advisors.

Before joining Canaan in 2002, Steve helped found and managed multiple startups, including Radiology Management Science (RMS) where he was CEO for 6 years, as well as OmniSonics and TeleRad. Prior to those companies, Steve was a strategic pharmaceutical consultant for Arthur D.Little. He was a Ewing Marion Kauffman Fellow, where he participated in an educational program that develops future leaders in venture capital.

Steve obtained his B.A. from Dartmouth College, an M.A. in the history of science from Harvard, and his medical degree from The University of Rochester. He completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).

Paul Touhey

Board Member and Executive Chairman Invisible Sentinel, Inc.

Paul has more than 25 years of medical device industry experience. He is currently the Executive Chairman of Invisible Sentinel Inc., a molecular diagnostics company. He serves as Chairman of the Board of Directors of TELA Bio, Inc., and is on the Board of Directors of Cytovas, a company focused on predicting cardiovascular events.

Paul is the former President/CEO and member of the Board of Directors of Fujirebio Diagnostics, Inc. (FDI), the world’s premier cancer diagnostics company. He joined FDI in 1998 when they acquired the Diagnostics Division of Centocor Inc. He had joined Centocor in 1985 and held a variety of positions including Senior Vice President of Operations. Prior to his roles at FDI and Centocor, Paul worked for Johnson & Johnson handling a variety of positions of increasing levels of responsibility and management.

Paul received his Bachelor of Arts degree in Political Science from Temple University and has chaired and/or is a current member of numerous industry trade associations and philanthropic organizations, and he continues to serve as an advisor to FDI.